Bayer

689 articles with Bayer

• Bayer and Systems Oncology Sign Exclusive License Agreement for Investigational Breast Cancer Treatment Approach ERSO™

  9/15/2020

  Bayer has entered into an exclusive global license agreement with Systems Oncology, LLC, for ERSO™, a compound in pre-clinical development for metastatic Estrogen Receptor (ER) positive, breast cancer. ERSO is a small molecule activator of the Unfolded Protein Response (UPR) in ER-positive breast cancer cells. ERSO’s mechanism of action is a therapeutic approach being investigated in women with metastatic ER-positive bre

• Bayer: Supervisory Board Extends CEO Werner Baumann’s Contract Until the End of April 2024

  9/10/2020

  The Supervisory Board of Bayer AG has unanimously decided to extend the contract of Werner Baumann, Chairman of the Board of Management, until April 30, 2024.

• Bayer Completes Acquisition of the UK-based Biotech Company KaNDy Therapeutics Ltd.

  9/9/2020

  Bayer, a global leader in women’s healthcare, announced that, further to its press release on August 11, 2020, Bayer completed the acquisition of UK-based biotech company KaNDy Therapeutics Ltd. to expand its drug development pipeline in women’s healthcare.

• Bayer Collaborates with Recursion to Strengthen Digital Drug Discovery and Advance New Therapies for Fibrotic Diseases

  9/9/2020

  Digitally-powered drug discovery to address fibrotic diseases with previously undiscovered mechanisms and to deliver novel therapies to patients faster

•  Bayer to Showcase New Data from Evolving Oncology Portfolio at ESMO Virtual Congress 2020

  9/8/2020

  Long-term efficacy and safety results of an integrated data set for Vitrakvi® (larotrectinib), as well as sub-analyses, to be presented in poster sessions

• Bayer Phase IV Study Met its Primary Endpoint in PAH Patients Who Had Transitioned to Adempas® (riociguat) After Insufficient Response to PDE5 Inhibitors

  9/7/2020

  Outcomes from the randomized, controlled, open-label REPLACE study included results from 226 patients with pulmonary arterial hypertension (PAH)

• Bayer Announces Resolution of U.S. Essure™ Claims

  8/20/2020

  Bayer announced today that it has reached agreements with plaintiff law firms to resolve approximately 90% of the nearly 39,000 total filed and unfiled U.S. Essure™ claims involving women who allege device-related injuries

• FDA Approves Gadavist® (gadobutrol) Imaging Bulk Package

  8/13/2020

  FDA Approves Gadavist ® (gadobutrol) Imaging Bulk Package The first and only gadolinium-based contrast agent with an FDA-approved Imaging Bulk Package presentation for multi-patient dosing with a device (e.g. transfer spike) cleared for use with Gadavist IBP in a room designated for radiological procedures with IV contrast

• Forbion Portfolio Company, KaNDy Therapeutics, to Be Acquired by Bayer

  8/11/2020

  Forbion, a leading European life sciences venture capital firm, announces that Bayer, a global leader in women’s healthcare, will acquire the UK-based biotech KaNDy Therapeutics Ltd.

• Bayer to Acquire UK-Based Biotech KaNDy Therapeutics Ltd.

  8/11/2020

  Bayer®, a leader in women’s healthcare, and KaNDy Therapeutics Ltd, a UK clinical-stage biotech company, announced that Bayer will acquire KaNDy Therapeutics Ltd. to expand its drug development pipeline in women’s healthcare.

• 

  Bayer Bolsters Women's Health Pipeline with Acquisition of KaNDy Therapeutics

  8/11/2020

  With a $425 million upfront payment, Bayer bolstered its women’s healthcare pipeline with the acquisition of U.K.-based KaNDy Therapeutics and its investigational treatment for menopause.

• Bayer Names Lori Moore as Vice President, Head of U.S. Pharmaceutical Communications

  8/10/2020

  Lori Moore, former Managing Director at Deloitte, will be joining Bayer as Vice President, Head of Pharmaceutical Communications in the United States, the company announced

• U.S. Food and Drug Administration Approves Lampit® (nifurtimox) for the Treatment of Chagas Disease in Children

  8/7/2020

  U.S. Food and Drug Administration Approves Lampit ® (nifurtimox) for the Treatment of Chagas Disease in Children Only Chagas disease treatment approved in U.S. for use in children from birth to less than 18 years of age 1 New, dividable tablet specially formulated to disperse in water to assist in administration for pediatric patients 1-3

• Bayer and Direct Relief Team Up to Help Remove Barriers So More Women Can Gain Access to Contraceptives

  8/5/2020

  Building on its more than 50-year commitment to women’s healthcare, today Bayer launched the We’re for Her initiative, which includes a partnership with the humanitarian organization Direct Relief that will help break down barriers so more women across the United States can access contraceptives and make

• Bayer Continues to Earn Top Marks in 2020 Disability Equality Index

  7/20/2020

  For the second consecutive year, Bayer U.S. was recognized as a Best Place to Work for Disability Inclusion, earning a score of 90 in the 2020 Disability Equality Index (DEI). Bayer’s DEI score improved from 2019, recognizing the company’s continued growth. DEI is the most comprehensive disability inclusion assessment tool des

• 

  Clinical Catch-Up: July 6-10

  7/13/2020

  Everybody seems to be back to work after the U.S. 4th of July holiday. Here’s a look at last week’s clinical trial updates.

• Bayer’s Finerenone Meets Primary Endpoint in Phase III FIDELIO-DKD Renal Outcomes Study in Patients With Chronic Kidney Disease and Type 2 Diabetes

  7/9/2020

  Finerenone reduced the combined primary endpoint of risk of chronic kidney disease progression, kidney failure or kidney death versus placebo when added to standard of care

• Bayer announces agreements to resolve major legacy Monsanto litigation

  6/24/2020

  Bayer announced today a series of agreements that will substantially resolve major outstanding Monsanto litigation, including U.S. Roundup™ product liability litigation, dicamba drift litigation and PCB water litigation.

• Bayer Consumer Health Makes Leadership Changes

  6/23/2020

  Two top Bayer Consumer Health executives are taking on new responsibilities due to strategic moves the business is making in its executive team to strengthen its position as a leader in consumer healthcare in the North America region.

• Luxxur™ Herbicide Knocks out Wild Oat in Wheat Fields

  6/18/2020

  New Bayer herbicide provides excellent control of wild oat, plus other grass and broadleaf weeds in durum, spring and winter wheat